granisetron intravenous / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 14 Diseases   3 Trials   3 Trials   126 News 


12»
  • ||||||||||  granisetron intravenous / Generic mfg.
    Trial completion date, Trial primary completion date:  Comparison Between IT Fentanyl and IV Granisetron in Prevention of Vomiting in CS Under Spinal Anesthesia (clinicaltrials.gov) -  Apr 18, 2023   
    P=N/A,  N=90, Recruiting, 
    Ondansetron provides better hemodynamic stability, earlier onset of the sensory and motor blocks as well as prolonged duration of sensory and motor blocks, and duration of analgesia compared to granisetron. Trial completion date: Jan 2023 --> Jan 2024 | Trial primary completion date: Dec 2022 --> Aug 2023
  • ||||||||||  granisetron intravenous / Generic mfg.
    Does the timing of intravenous prophylactic infusion of granisetron improve hemodynamic profile during spinal anesthesia in elective lower-abdominal Surgery? ([VIRTUAL]) -  Nov 25, 2021 - Abstract #Euroanaesthesia2021Euroanaesthesia_1018;    
    It was concluded that prophylactic IV administration of 3 mg of granisetron or 8 mg of ondansetron before spinal anesthesia results in a significantly lower ephedrine requirement compared to placebo. The early prophylaxis with iv granisetron compared to its late administration, effectively mitigates the spinal anesthesia-induced cardiovascular changes with significant reduction of nausea/vomiting incidence and atropine/ephedrine doses during elective lower-abdominal Surgery.
  • ||||||||||  Sancuso (granisetron) / Solasia
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Effect of Granisetron on Morphine Induced Pruritus in Cesarean Section (clinicaltrials.gov) -  Sep 9, 2021   
    P2,  N=80, Completed, 
    The early prophylaxis with iv granisetron compared to its late administration, effectively mitigates the spinal anesthesia-induced cardiovascular changes with significant reduction of nausea/vomiting incidence and atropine/ephedrine doses during elective lower-abdominal Surgery. Not yet recruiting --> Completed | N=40 --> 80 | Trial completion date: Jul 2019 --> Oct 2020 | Trial primary completion date: May 2019 --> Oct 2020
  • ||||||||||  Sancuso (granisetron) / Solasia
    Enrollment change, Trial withdrawal:  Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years (clinicaltrials.gov) -  Mar 22, 2021   
    P1,  N=0, Withdrawn, 
    Trial completion date: Apr 2023 --> Apr 2025 | Trial primary completion date: Apr 2022 --> Apr 2025 N=16 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  Retrospective data, Review, Journal:  Antiemetics in Children With Acute Gastroenteritis: A Meta-analysis. (Pubmed Central) -  Jun 28, 2020   
    Ondansetron is the only intervention that revealed an effect on the cessation of vomiting, on preventing hospitalizations, and in reducing the need for intravenous rehydration. Ondansetron was also considered a safe intervention.
  • ||||||||||  melphalan / Generic mfg.
    Journal:  Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma. (Pubmed Central) -  Apr 29, 2020   
    Recently, a propylene glycol-free melphalan formulation (PG-free MEL; Evomela®) was approved by the United States Food and Drug Administration as an ASCT-conditioning regimen for MM...After Day +0, there were no differences in terms of hospitalizations, neutropenic fevers, intravenous granisetron requirement, World Health Organization grade ≥ 2 oral/esophageal mucositis, intravenous fluid requirement, or narcotic requirement...Day + 100 hematologic responses and progression-free survival after ASCT were comparable. In summary, we demonstrate that switching to PG-free MEL did not significantly reduce short-term complications of ASCT or improve outcomes in MM.
  • ||||||||||  Trial completion, Surgery, Metastases:  PRECISO: Observational Study of Perioperative Chemotherapy in Gastric Cancer (clinicaltrials.gov) -  Apr 24, 2020   
    P=N/A,  N=61, Completed, 
    In summary, we demonstrate that switching to PG-free MEL did not significantly reduce short-term complications of ASCT or improve outcomes in MM. Active, not recruiting --> Completed
  • ||||||||||  granisetron intravenous injection / Generic mfg.
    Clinical, Journal:  Effect of acupuncture on hormone level in patients with gastrointestinal dysfunction after general anesthesia: A study protocol for a randomized controlled trial. (Pubmed Central) -  Apr 9, 2020   
    Therapies will be performed 30 min once after operation, the experimental group will be treated with acupuncture, while the control group will receive intravenous injection of granisetron...A standardized and scientific clinical trial is conducted to assess the efficacy and safety of acupuncture for gastrointestinal dysfunction after laparoscopic cholecystectomy under general anesthesia. The aim is to objectively evidence and improves the clinical practice of acupoint prescription, as an attempt to promote the clinical application of this technology.
  • ||||||||||  ondansetron intravenous / Generic mfg., granisetron oral / Generic mfg., granisetron intravenous / Generic mfg.
    Biomarker, Trial completion:  Pharmacogenomics and Post-Operative Nausea and Vomiting (clinicaltrials.gov) -  Mar 31, 2020   
    P4,  N=92, Completed, 
    The aim is to objectively evidence and improves the clinical practice of acupoint prescription, as an attempt to promote the clinical application of this technology. Recruiting --> Completed
  • ||||||||||  granisetron intravenous / Generic mfg.
    Trial completion:  Staccato (clinicaltrials.gov) -  Mar 3, 2020   
    P1,  N=36, Completed, 
    We could not find meaningful statistical differences between two arms, regarding CR rate on acute and delayed CINV. Recruiting --> Completed
  • ||||||||||  Sancuso (granisetron) / Solasia
    Trial completion date, Trial primary completion date:  Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years (clinicaltrials.gov) -  Jan 21, 2020   
    P1,  N=16, Not yet recruiting, 
    Recruiting --> Completed Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2020
  • ||||||||||  granisetron intravenous / Generic mfg.
    New P1 trial:  Staccato (clinicaltrials.gov) -  Dec 15, 2019   
    P1,  N=36, Recruiting, 
  • ||||||||||  dexamethasone / generics
    Clinical, Journal:  A Randomized Placebo-Controlled Trial of Prophylactic Dexamethasone for Transcatheter Arterial Chemoembolization. (Pubmed Central) -  Oct 30, 2019   
    Our study suggests that Granisetron is more effective in preventing PONV during 6 hours after the surgery in comparison with Ondansetron which makes it a favourable alternative for preventing PONV. The dexamethasone regimen was more effective than the control regimen in preventing TACE-induced fever, anorexia, and nausea/vomiting in patients with HCC.
  • ||||||||||  Imperan (metoclopramide) / Generic Mfg.
    Clinical, Journal:  Efficacy of Palonosetron as Antiemetic Prophylaxis for Post Operative Patients. (Pubmed Central) -  Aug 9, 2019   
    Nausea was found 3(8.8%) in group A, 8(23.5%) in group B and 6(17.6%) in group C. Vomiting was found 3(8.8%) in group A, 10(29.4%) in group B and 7(20.6%) in group C. Vomiting was significantly higher in group B compare with group A. For group B rescue anti-emetic injection motilon (metoclopramide hydrochloride) 5mg IV slowly was given. Palonosetron is effective prophylaxis against post operative nausea and vomiting.
  • ||||||||||  Preclinical, Journal:  Colitis-induced alterations in response properties of visceral nociceptive neurons in the rat caudal medulla oblongata and their modulation by 5-HT3 receptor blockade. (Pubmed Central) -  Aug 1, 2019   
    Intravenous granisetron (1 or 2 mg/kg) produced the dose-dependent suppression of the ongoing and evoked firing of CRD-excited cells within both the CVLM and NTS in normal conditions as well as was able to substantially reduce excitability of the caudal medullary neurons in the presence of colonic inflammation, arguing for the potential efficacy of the 5-HT receptor blockade with granisetron against both acute and inflammatory abdominal pain. Taken together, the data obtained can contribute to a deeper understanding of supraspinal serotonergic mechanisms responsible for the persistence of visceral hypersensitivity and hyperalgesia triggered by colonic inflammation.
  • ||||||||||  ondansetron intravenous / Generic mfg., granisetron oral / Generic mfg., granisetron intravenous / Generic mfg.
    Biomarker, Trial completion date, Trial primary completion date:  Pharmacogenomics and Post-Operative Nausea and Vomiting (clinicaltrials.gov) -  Jun 3, 2019   
    P4,  N=100, Recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Mar 2020 --> May 2019 | Trial primary completion date: Mar 2020 --> May 2019 Trial completion date: Oct 2019 --> Feb 2020 | Trial primary completion date: Apr 2019 --> Dec 2019
  • ||||||||||  ondansetron intravenous / Generic mfg., granisetron oral / Generic mfg., granisetron intravenous / Generic mfg.
    Biomarker, Trial completion date, Trial primary completion date:  Pharmacogenomics and Post-Operative Nausea and Vomiting (clinicaltrials.gov) -  Jan 10, 2019   
    P4,  N=100, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Aug 2020 --> Mar 2020 | Trial primary completion date: Aug 2020 --> Mar 2020 Trial completion date: Feb 2019 --> Oct 2019 | Trial primary completion date: Nov 2018 --> Apr 2019